Mutual of America Capital Management LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Mutual of America Capital Management LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 11,024 shares of the biopharmaceutical company’s stock after selling 868 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,198,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $226,000. Patton Fund Management Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $210,000. HB Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 2.3% in the second quarter. HB Wealth Management LLC now owns 2,049 shares of the biopharmaceutical company’s stock valued at $1,076,000 after acquiring an additional 46 shares in the last quarter. Finally, PGGM Investments raised its position in Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after purchasing an additional 51,900 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $751.13 on Thursday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $78.94 billion, a P/E ratio of 17.99, a PEG ratio of 2.01 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a fifty day moving average price of $758.43 and a 200 day moving average price of $647.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the company posted $12.46 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on REGN shares. Evercore ISI lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. UBS Group lifted their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Finally, BMO Capital Markets lifted their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $784.77.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.